Literature DB >> 26293411

Synthetic Cannabinoid Abuse in Adolescents: A Case Series.

Gulser Esen Besli1, Mehmet Alper Ikiz1, Sema Yildirim1, Selcuk Saltik2.   

Abstract

BACKGROUND: Synthetic cannabinoids, referred to as "Bonzai" in Turkey, are relatively new recreational drugs of abuse. Although the use of synthetic cannabinoids has been dramatically increasing in young populations in many countries, their adverse effects are not well known.
OBJECTIVES: To report on the clinical features and social history of pediatric patients with a diagnosis of synthetic cannabinoid intoxication and to highlight the dangers of these drugs to public health.
METHODS: We retrospectively reviewed 16 cases presenting to our Emergency Department (ED) with synthetic cannabinoid intoxication in the last 10 months. Usage characteristics and the psychoactive, physical, and metabolic effects of synthetic cannabinoids were analyzed.
RESULTS: The mean age of the 16 patients with a diagnosis of synthetic cannabinoid intoxication was 15.4 ± 1.7 years (15 males, 1 female). The most common physical symptoms were eye redness, nausea/vomiting, sweating, and altered mental status; the main psychoactive findings were agitation, anxiety, hallucinations, and perceptual changes. We observed hypotension and bradycardia in 8 (50%) and 5 (31.3%) of the patients, respectively. Although most patients were discharged from the ED, 25% were transferred to an intensive care unit. They all had reduced school attendance and performance. The rates of cigarette smoking and alcohol drinking were also significantly higher.
CONCLUSION: Synthetic cannabinoids are unsafe and potentially harmful drugs of abuse; they may even cause life-threatening effects. It is important for pediatricians to be familiar with the signs and symptoms of consumption of synthetic cannabinoid products. Education of parents, teachers, and adolescents about the potential health risks of using these products is essential.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bonzai; adolescents; intoxication; spice drugs; synthetic cannabinoids

Mesh:

Substances:

Year:  2015        PMID: 26293411     DOI: 10.1016/j.jemermed.2015.06.053

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  14 in total

1.  Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review.

Authors:  Justin P Reinert; O'Neill Niyamugabo; Kiersi S Harmon; Norman E Fenn
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

2.  Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones.

Authors:  Megan E Patrick; Patrick M O'Malley; Deborah D Kloska; John E Schulenberg; Lloyd D Johnston; Richard A Miech; Jerald G Bachman
Journal:  Drug Alcohol Rev       Date:  2015-12-29

Review 3.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

4.  Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis.

Authors:  Francois R Lamy; Raminta Daniulaityte; Ramzi W Nahhas; Monica J Barratt; Alan G Smith; Amit Sheth; Silvia S Martins; Edward W Boyer; Robert G Carlson
Journal:  Int J Drug Policy       Date:  2017-06-01

5.  Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity.

Authors:  Sarah Ann R Anderson; Anna M Oprescu; Diane Calello; Andrew Monte; Peter S Dayan; Yasmin L Hurd; Alex F Manini
Journal:  Pediatrics       Date:  2019-07-08       Impact factor: 7.124

Review 6.  What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review.

Authors:  Emilie Jouanjus; Valentin Raymond; Maryse Lapeyre-Mestre; Valérie Wolff
Journal:  Curr Atheroscler Rep       Date:  2017-06       Impact factor: 5.113

Review 7.  Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.

Authors:  Cristina Miliano; Giovanni Serpelloni; Claudia Rimondo; Maddalena Mereu; Matteo Marti; Maria Antonietta De Luca
Journal:  Front Neurosci       Date:  2016-04-19       Impact factor: 4.677

8.  Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients.

Authors:  Merih Altintas; Leman Inanc; Gamze Akcay Oruc; Selim Arpacioglu; Huseyin Gulec
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-02       Impact factor: 2.570

Review 9.  Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.

Authors:  Aviv M Weinstein; Paola Rosca; Liana Fattore; Edythe D London
Journal:  Front Psychiatry       Date:  2017-08-23       Impact factor: 4.157

10.  "Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.

Authors:  Frederick S Barrett; Nicolas J Schlienz; Natalie Lembeck; Muhammad Waqas; Ryan Vandrey
Journal:  Cannabis Cannabinoid Res       Date:  2018-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.